{
    "clinical_study": {
        "@rank": "119435", 
        "acronym": "CREDIT-III", 
        "arm_group": {
            "arm_group_label": "EXCEL-II DES", 
            "description": "Using EXCEL-II biodegradable polymer sirolimus-eluting stent treating CAD"
        }, 
        "biospec_descr": {
            "textblock": "According to the CREATE (Multi - Center Registry of Excel Biodegradable Polymer Drug Eluting\n      Stent) registration results show that ExcelTM drug-eluting stents implanted an average of 12\n      months, target lesion (TLF) the failure rate of 6.7%.Will this study expected target lesion\n      group stent failure rate estimate of 6.7%, the target is 9.5%;Test hypothesis: bilateral\n      0.05% 0.05%, master degree, clinical follow-up requirements is more than 95%, this research\n      need at least 829 patients, remove the CREDIT II randomized controlled study can provide the\n      number of cases of test group 208 examples, this study still need to be included in the 621\n      patients."
        }, 
        "biospec_retention": "None Retained", 
        "brief_summary": {
            "textblock": "The study aims to further assess the safety, efficacy and the performance of its delivery\n      system of the new generation Sirolimus-eluting stent of JWMS up to five years."
        }, 
        "brief_title": "EXCEL-II DES to Treat the Patients With de Novo Coronary Artery Lesions. (CREDIT-III)", 
        "completion_date": {
            "#text": "June 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "1. A prospective, a single set, multicenter clinical trial;\n\n        2. The primary in situ in patients with coronary heart disease;\n\n        3. The center of: 28 (the actual number of center shall prevail);The plan selected 621\n           patients;(where the total number of cases in 2.25 mm specification not less than 30\n           cases, 5 cases each specification of not less than 2.25 mm.)\n\n        4. Clinical follow-up time points: 1 months, 6 months, 12 months and 18 months of a year\n           and 2 years to 5 years follow-up; This test by an independent coronary angiography core\n           laboratories, data management and statistical center, clinical end points to judge\n           committee and clinical monitoring of all relevant clinical and imaging data collecting,\n           sorting, statistical analysis and judgement.All the selected patients within five years\n           continuous follow-up tracking (phone or outpatient follow-up), to observe the happening\n           of adverse events to the forward of the second generation of EXCEL drug-eluting stents\n           (des) system security to make more accurate and credible evaluation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        1.18yrs\u2264Age\u226475yrs . 2..stability and unstable angina pectoris (AP), chronic myocardial\n        infarction (OMI) or confirmed (myocardial ischemia; 3.De novo lesion at native coronary\n        artery(Up to four target lesions). 4.Lesion length \u226460mm. 5.RVD 2.25mm\uff5e4.0mm. 6.DS%\u226570% by\n        visual estimation. 7.Coronary artery bypass surgery (coronary artery bypass grafting)\n        patients. 8.Subjects are willing to follow the specified requirements follow-up.\n\n        9.To understand the purpose of testing, voluntary and signed informed consent, willing to\n        accept the imaging and clinical follow-up of subjects.\n\n        Exclusion Criteria:\n\n          1. AMI within 7 days.\n\n          2. Left main lesion, transplant vasculopathy and stent restenosis lesion;\n\n          3. Severe calcified lesion unable to predilate.\n\n          4. The distortion of the stent was hampered by lesions.\n\n          5. NYHA\u2265\u2162 or LVEF\uff1c35%.\n\n          6. Prior stenting within 1 year.\n\n          7. Pregnancy or lactation, and plan in postoperative pregnancy or lactation.\n\n          8. Subjects had bleeding tendency or blood coagulation dysfunction or PCI\n             contraindications, or anticoagulant therapy taboo or can't continue DAPT healers at\n             least 1 year.\n\n          9. There are other diseases (such as cancer,malignant tumor ,congestive heart\n             failure,organ transplantation or candidate) or abuse history (alcohol cocaine heroin,\n             etc.), scheme compliance is poor, interference related data explanation or the\n             limited life (< 1 year).\n\n         10. To aspirin heparin clopidogrel cobalt chromium alloy rapamycin PLA polymer contrast\n             agent of one of allergy.\n\n         11. Serious liver and kidney function is not complete person(ALT and AST were three times\n             greater than the upper limit of normal).\n\n         12. Rounding out the top participated in other clinical trials have not reached the main\n             research the finish time limit.\n\n         13. The researchers determine adherence is poor, could not finish my study in accordance\n             with the requirements of the subjects."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "the Patients With de Novo Coronary Artery Lesions"
            }
        }, 
        "enrollment": {
            "#text": "621", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02027870", 
            "org_study_id": "CREDIT-III-131113"
        }, 
        "intervention": {
            "arm_group_label": "EXCEL-II DES", 
            "description": "EXCEL-II biodegradable polymer sirolimus-eluting stent implantation", 
            "intervention_name": "EXCEL-II biodegradable polymer sirolimus-eluting stent", 
            "intervention_type": "Device"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Chlorhexidine", 
                "Chlorhexidine gluconate", 
                "Sirolimus", 
                "Everolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "DES", 
            "CAD", 
            "EXCEL-II", 
            "JWMS", 
            "PCI"
        ], 
        "lastchanged_date": "January 2, 2014", 
        "location": {
            "contact": {
                "email": "wanggeng69@hotmail.com", 
                "last_name": "geng wang, PhD", 
                "phone": "+86 13309886393"
            }, 
            "contact_backup": {
                "email": "fengying_6@163.com", 
                "last_name": "he zhou", 
                "phone": "+86 13309888541"
            }, 
            "facility": {
                "address": {
                    "city": "Shenyang", 
                    "country": "China", 
                    "state": "Liaoning", 
                    "zip": "110015"
                }, 
                "name": "Shenyang Northern Hospital"
            }, 
            "investigator": {
                "last_name": "Wang Geng, PhD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Prospective Multicenter Single-Arm Observational Registry Study to Assess the Safety and Efficacy of EXCEL-II With Sirolimus Eluting Stent for the Treatment of Patients With de Novo Coronary Artery . (CREDIT-III Trial)", 
        "overall_contact": {
            "email": "gangtao.wang@jwmsgrp.com", 
            "last_name": "gangtao wang", 
            "phone": "+86 010 68068918"
        }, 
        "overall_contact_backup": {
            "last_name": "yan lin", 
            "phone": "+86 010 68068918"
        }, 
        "overall_official": {
            "affiliation": "Shen yang Northern hospital", 
            "last_name": "yaling Han, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Device-related cardiovascular composite endpoint, including cardiac death, target vessel MI and clinically driven TLR at 12 months post procedure", 
            "measure": "The Target Lesion Failure(TLF) as the primary endpoint at 12-month", 
            "safety_issue": "Yes", 
            "time_frame": "12months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02027870"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Stent implantation success rate", 
                "safety_issue": "Yes", 
                "time_frame": "5 Years"
            }, 
            {
                "measure": "TLF, cardiovascular composite endpoints, ARC defined stent thrombosis", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, 6 months, and 2-5 years"
            }
        ], 
        "source": "JW Medical Systems Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "JW Medical Systems Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "5 Years", 
        "verification_date": "January 2014"
    }
}